BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More Details
Mediocre balance sheet with questionable track record.
Share Price & News
How has BioNTech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: BNTX's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BNTX exceeded the US Biotechs industry which returned 26.8% over the past year.
Return vs Market: BNTX exceeded the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is BioNTech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StAnalysts Just Made A Massive Upgrade To Their BioNTech SE (NASDAQ:BNTX) Forecasts
1 month ago | Simply Wall StIs BioNTech SE's (NASDAQ:BNTX) Shareholder Ownership Skewed Towards Insiders?
2 months ago | Simply Wall StShareholders Are Thrilled That The BioNTech (NASDAQ:BNTX) Share Price Increased 281%
Is BioNTech undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BNTX ($129.64) is trading above our estimate of fair value ($51.16)
Significantly Below Fair Value: BNTX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BNTX is poor value based on its PE Ratio (1683.4x) compared to the US Biotechs industry average (30.1x).
PE vs Market: BNTX is poor value based on its PE Ratio (1683.4x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: BNTX is poor value based on its PEG Ratio (1906.8x)
Price to Book Ratio
PB vs Industry: BNTX is overvalued based on its PB Ratio (19.1x) compared to the US Biotechs industry average (3.7x).
How is BioNTech forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNTX's forecast earnings growth (0.9% per year) is below the savings rate (2%).
Earnings vs Market: BNTX's earnings (0.9% per year) are forecast to grow slower than the US market (18.5% per year).
High Growth Earnings: BNTX's earnings are forecast to grow, but not significantly.
Revenue vs Market: BNTX's revenue (8.8% per year) is forecast to grow slower than the US market (9.9% per year).
High Growth Revenue: BNTX's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BNTX's Return on Equity is forecast to be low in 3 years time (8.8%).
How has BioNTech performed over the past 5 years?
Last years revenue growth
Earnings and Revenue History
Quality Earnings: BNTX has a large one-off gain of €243.4M impacting its December 31 2020 financial results.
Growing Profit Margin: BNTX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: BNTX has become profitable over the past 5 years.
Accelerating Growth: BNTX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BNTX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: BNTX's Return on Equity (1.1%) is considered low.
How is BioNTech's financial position?
Financial Position Analysis
Short Term Liabilities: BNTX's short term assets (€1.7B) exceed its short term liabilities (€606.0M).
Long Term Liabilities: BNTX's short term assets (€1.7B) exceed its long term liabilities (€340.8M).
Debt to Equity History and Analysis
Debt Level: BNTX's debt to equity ratio (11.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BNTX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BNTX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if BNTX's interest payments on its debt are well covered by EBIT.
What is BioNTech current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BNTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BNTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BNTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BNTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BNTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ugur Sahin (54 yo)
Prof. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board. Prof. Sahin co-Founded Ganymed Pharmaceuticals AG. Prof. Sahin al...
CEO Compensation Analysis
Compensation vs Market: Ugur's total compensation ($USD19.71M) is above average for companies of similar size in the US market ($USD10.98M).
Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.
Experienced Management: BNTX's management team is seasoned and experienced (9.9 years average tenure).
Experienced Board: BNTX's board of directors are seasoned and experienced ( 13.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.5%.
BioNTech SE's company bio, employee growth, exchange listings and data sources
- Name: BioNTech SE
- Ticker: BNTX
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$31.311b
- Shares outstanding: 241.52m
- Website: https://www.biontech.de
Number of Employees
- BioNTech SE
- An der Goldgrube 12
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/13 22:40|
|End of Day Share Price||2021/04/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.